[go: up one dir, main page]

WO2001088159A3 - Cd28 synthebody for the modulation of immune responses - Google Patents

Cd28 synthebody for the modulation of immune responses Download PDF

Info

Publication number
WO2001088159A3
WO2001088159A3 PCT/US2001/015707 US0115707W WO0188159A3 WO 2001088159 A3 WO2001088159 A3 WO 2001088159A3 US 0115707 W US0115707 W US 0115707W WO 0188159 A3 WO0188159 A3 WO 0188159A3
Authority
WO
WIPO (PCT)
Prior art keywords
variants
binding
cdr
binding sequence
synthebody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/015707
Other languages
French (fr)
Other versions
WO2001088159A2 (en
Inventor
Ronald Martin Burch
Daniel Andrew Soltis
Paul Kaladas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Priority to AU2001261628A priority Critical patent/AU2001261628A1/en
Publication of WO2001088159A2 publication Critical patent/WO2001088159A2/en
Publication of WO2001088159A3 publication Critical patent/WO2001088159A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides variants of an immunoglobulin variable domain having at least one CDR region and framework regions flanking the CDR. The variant includes (a) the CDR region having added or substituted therein at least one binding sequence and (b) the flanking framework regions, wherein the binding sequence is heterologous to the CDR and is a binding sequence from a binding site of a binding pair, and wherein the binding sequence is a CD80 and/or CD86 receptor-binding portion of CD28. Also disclosed and claimed are molecules, immunoglobulins, and compositions including these variants, as well as nucleic acids and expression vectors encoding these variants, and methods of using the variants for immunotherapy.
PCT/US2001/015707 2000-05-16 2001-05-16 Cd28 synthebody for the modulation of immune responses Ceased WO2001088159A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001261628A AU2001261628A1 (en) 2000-05-16 2001-05-16 Cd28 synthebody for the modulation of immune responses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20448300P 2000-05-16 2000-05-16
US60/204,483 2000-05-16

Publications (2)

Publication Number Publication Date
WO2001088159A2 WO2001088159A2 (en) 2001-11-22
WO2001088159A3 true WO2001088159A3 (en) 2002-04-11

Family

ID=22758081

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/015707 Ceased WO2001088159A2 (en) 2000-05-16 2001-05-16 Cd28 synthebody for the modulation of immune responses

Country Status (2)

Country Link
AU (1) AU2001261628A1 (en)
WO (1) WO2001088159A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US9528088B2 (en) 2002-06-28 2016-12-27 Life Technologies Corporation Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10240418A1 (en) * 2002-09-02 2004-03-11 Avontec Gmbh Formulation for introducing nucleic acids into eukaryotic cells
WO2005021595A1 (en) * 2003-08-28 2005-03-10 Euro-Celtique S.A. Methods of antibody engineering using antibody display rules
CA2594356C (en) 2005-01-05 2018-07-17 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
AT503902B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING IMMUNE LOBULINS
AT503889B1 (en) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F MULTIVALENT IMMUNE LOBULINE
EP3241842B1 (en) 2007-06-26 2024-01-31 F-star Therapeutics Limited Display of binding agents
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
HRP20180045T1 (en) 2008-10-02 2018-03-23 Aptevo Research And Development Llc Cd86 antagonist multi-target binding proteins
CN103724432B (en) * 2009-11-30 2016-06-08 霍夫曼-拉罗奇有限公司 The antibody that the tumour of SLC34A2 (TAT211=SEQID2) is expressed in treatment and diagnosis
ES2791758T3 (en) 2011-12-22 2020-11-05 Hoffmann La Roche Organization of expression vectors, methods of generating novel production cells and their use for recombinant production of polypeptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022377A1 (en) * 1995-01-19 1996-07-25 Armitage, Ian, M. Activation of t-cells by modified, antigenic immunoglobulins
WO1999025378A1 (en) * 1997-11-14 1999-05-27 Euro-Celtique, S.A. Immunoglobulin molecules having a synthetic variable region and modified specificity
WO1999029344A1 (en) * 1994-09-19 1999-06-17 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029344A1 (en) * 1994-09-19 1999-06-17 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response
WO1996022377A1 (en) * 1995-01-19 1996-07-25 Armitage, Ian, M. Activation of t-cells by modified, antigenic immunoglobulins
WO1999025378A1 (en) * 1997-11-14 1999-05-27 Euro-Celtique, S.A. Immunoglobulin molecules having a synthetic variable region and modified specificity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Peptides for the new millennium", 2000, KLUWER ACADEMIC PUBL., DORDRECHT, THE NETHERLANDS, XP001031358 *
A. TRUNEH ET AL.: "Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): Analysis by site-directed mutagenesis.", MOLECULAR IMMUNOLOGY, vol. 33, no. 3, February 1996 (1996-02-01), Oxford, GB, pages 321 - 334, XP001031316 *
H. ZAGHOUANI ET AL.: "Engineered immunoglobulin molecules as vehicles for T cell epitopes.", INTERNATIONAL REVIEWS OF IMMUNOLOGY, vol. 10, no. 2-3, 1993, Switzerland, pages 265 - 278, XP002177699 *
J. COOK ET AL.: "Recombinant antibodies containing an engineered B-cell epitope capable of eliciting conformation-specific antibody responses.", VACCINE, vol. 13, no. 18, December 1995 (1995-12-01), Guildford, GB, pages 1770 - 1778, XP004057383 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US9528088B2 (en) 2002-06-28 2016-12-27 Life Technologies Corporation Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation

Also Published As

Publication number Publication date
WO2001088159A2 (en) 2001-11-22
AU2001261628A1 (en) 2001-11-26

Similar Documents

Publication Publication Date Title
WO2001088159A3 (en) Cd28 synthebody for the modulation of immune responses
AU5736601A (en) Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
WO2002083738A1 (en) Cyclic single strand trispecific antibody
WO2001012804A3 (en) MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
WO2001055370A3 (en) MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
WO2002062850A3 (en) Hybrid antibodies and uses thereof
TWI319405B (en) Soluble ctla4 mutant molecules and uses thereof
WO2021173896A8 (en) Materials and methods for modulating an immune response
NO20012033D0 (en) Polyurethane prepolymers having alkoxysilane end groups, process for their preparation, their use in the preparation of sealants
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
CY1110695T1 (en) METHODS FOR CREATING A HIGH-TITLE AUTO-AID HEADLIFT PREPARATORY FORMATS
AU8127494A (en) Chimeric proteins comprising borrelia polypeptides: uses therefor
PL344475A1 (en) Bridged indenopyrrolocarbazoles
WO2002078613A3 (en) Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response
WO2002083910A3 (en) Sequence specific recombinase-based methods for producing intron containing vectors and compositions for use in practicing the same
WO2002040668A3 (en) Proteins and dna sequences underlying these proteins used for treating inflammations
ATE323166T1 (en) FRAGMENTS OF INTRON A OF CITOMEGALOVIRUS
WO2000061635A3 (en) Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment
WO1996031603A3 (en) Methods and compositions for regulating fadd
WO2003057843A8 (en) Methods and materials for modulating trpc4
DE69840326D1 (en) INCREASING IMMUNE RESPONSE USING TARGETED MOLECULES
DK0676965T3 (en) Method for reducing the immunogenicity of variable regions on antibodies
GB2375112A (en) Combinatorial protein domains
WO1998016255A3 (en) Stabilized conjugates of uncomplexed subunits of multimeric proteins
WO2023031943A3 (en) Cd28 shedding blocking agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP